Ligand and structure based hierarchical virtual screening cascade for finding novel epidermal growth factor receptor inhibitors

Chem Biol Drug Des. 2024 Jan;103(1):e14375. doi: 10.1111/cbdd.14375. Epub 2023 Oct 17.

Abstract

The epidermal growth factor receptor (EGFR) tyrosine kinase plays an important role in tumor formation and growth by mediating cell growth and other physiological processes. Therefore, EGFR is a promising target for the treatment of cancer. In this work, we combined ligand-based and structure-based virtual screening methods to identify novel EGFR inhibitors from a library of more than 103 thousand compounds. We first obtained hundreds of compounds with similar physiochemical properties through 3D molecular shape and electrostatic similarity screening with potent inhibitors AEE788 and Afatinib as queries. Next, we identified compounds with strong binding affinities to the EGFR pocket through molecular docking, which makes good use of the structure information of the receptor. After molecular scaffold analysis, our bioassay confirmed 13 compounds with EGFR inhibitory activity and three compounds had IC50 values below 1000 nM. In addition, we collected 5371 EGFR inhibitors from online databases, and clustered them into 7 groups by K-means method using their ECFP4 fingerprints as input. Each cluster had typical molecular fragments and corresponding activity characteristics, which could guide the design of EGFR inhibitors, and we concluded that the fragments from some of the hits are indicated in the highly active scaffolds.

Keywords: epidermal growth factor receptor inhibitors; molecular clustering; molecular docking; virtual screening.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Afatinib / therapeutic use
  • Antineoplastic Agents* / pharmacology
  • ErbB Receptors / metabolism
  • Humans
  • Ligands
  • Molecular Docking Simulation
  • Neoplasms* / drug therapy
  • Protein Kinase Inhibitors / chemistry

Substances

  • Protein Kinase Inhibitors
  • Ligands
  • ErbB Receptors
  • Afatinib
  • Antineoplastic Agents

Grants and funding